Patents by Inventor Eisaku Kondo
Eisaku Kondo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124571Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: ApplicationFiled: November 17, 2023Publication date: April 18, 2024Applicant: National University Corporation Okayama UniversityInventors: Masakiyo SAKAGUCHI, Shinichi TOYOOKA, Shuta TOMIDA, Kazuhiko SHIEN, Hiroki SATO, Rie KINOSHITA, Junichiro FUTAMI, Kota ARAKI, Mikio OKAZAKI, Eisaku KONDO, Yusuke INOUE, Akira YAMAUCHI
-
Patent number: 11858984Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: GrantFiled: April 15, 2019Date of Patent: January 2, 2024Assignees: National University Corporation Okayama University, Niigata University, National University Corporation Gunma UniversityInventors: Masakiyo Sakaguchi, Shinichi Toyooka, Shuta Tomida, Kazuhiko Shien, Hiroki Sato, Rie Kinoshita, Junichiro Futami, Kota Araki, Mikio Okazaki, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi
-
Patent number: 11447525Abstract: This peptide is composed of an amino acid sequence represented by general formula (I), and has a high degree of accumulation in cancer cells or cancer tissue in a digestive system. In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any of SEQ ID NOs: 1 to 3, (b) an amino acid sequence including a sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any of SEQ ID NOs: 1 to 3; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue, a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 1 but not more than 9.Type: GrantFiled: April 25, 2019Date of Patent: September 20, 2022Assignee: NIIGATA UNIVERSITYInventors: Eisaku Kondo, Ken Saito
-
Publication number: 20220175940Abstract: A peptide is composed of an amino acid sequence represented by general formula (I), and accumulates in cancer-associated fibroblasts. (In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any one of SEQ ID NOs: 1 to 4, (b) an amino acid sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any one of SEQ ID NOs: 1 to 4; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue, a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 0 but not more than 9.Type: ApplicationFiled: February 27, 2020Publication date: June 9, 2022Inventor: Eisaku KONDO
-
Publication number: 20210163537Abstract: This peptide is composed of an amino acid sequence represented by general formula (I), and has a high degree of accumulation in cancer cells or cancer tissue in a digestive system. (In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any of SEQ ID NOs: 1 to 3, (b) an amino acid sequence including a sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any of SEQ m NOs: 1 to 3; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 1 but not more than 9.Type: ApplicationFiled: April 25, 2019Publication date: June 3, 2021Applicant: Niigata UniversityInventors: Eisaku KONDO, Ken SAITO
-
Publication number: 20210054061Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: ApplicationFiled: April 15, 2019Publication date: February 25, 2021Applicants: National University Corporation Okayama University, NIIGATA UNIVERSITY, National University Corporation Gunma University, Kawasaki Gakuen Educational FoundationInventors: Masakiyo SAKAGUCHI, Shinichi TOYOOKA, Shuta TOMIDA, Kazuhiko SHIEN, Hiroki SATO, Rie KINOSHITA, Junichiro FUTAMI, Kota ARAKI, Mikio OKAZAKI, Eisaku KONDO, Yusuke INOUE, Akira YAMAUCHI
-
Patent number: 10668125Abstract: Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.Type: GrantFiled: October 21, 2016Date of Patent: June 2, 2020Assignee: Niigata UniversityInventors: Eisaku Kondo, Ken Saito
-
Publication number: 20180360903Abstract: The present invention provides a novel peptide that acts directly on pancreatic cancer cells and tissues and has highly-shifted accumulation thereto. Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS:1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS:1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.Type: ApplicationFiled: October 21, 2016Publication date: December 20, 2018Applicant: Niigata UniversityInventors: Eisaku Kondo, Ken Saito
-
Publication number: 20060089256Abstract: The present invention has as its object the provision of a platinum-rhodium catalyst for automotive exhaust gas wherein the exhaust gas purification catalyst is provided with resistance to lean conditions due to fluctuations in the exhaust gas atmosphere due to fuel cuts of the automobile engine and the catalyst itself is provided with heat resistance due to mounting in the high temperature region right near the engine. Further, the platinum-rhodium catalyst for automotive exhaust gas of the present invention is formed with a catalyst layer from a mixture of a platinum catalyst carrier substance comprised of 95 to 99.9 wt % of a first catalyst carrier substance comprised of either first cerium oxide or activated alumina stabilized by zirconium carrying 0.1 to 5 wt % of platinum, a rhodium catalyst-carrying powder comprised of a second catalyst carrier substance of a rare earth metal element-stabilized zirconium oxide carrying 0.Type: ApplicationFiled: October 20, 2005Publication date: April 27, 2006Inventors: Masanori Shimizu, Shingo Sakagami, Eisaku Kondo
-
Patent number: 6555497Abstract: An ammine solution which can be provided at low production cost, as compared with conventional ones. The ammine solution contains an ammine compound which contains at least one of platinum and palladium, and at least one kind of amine compound. By using the amine compound of which the boiling point is raised, as compared with that of ammonia, due to the substitution of substitution radicals for some of hydrogens in ammonia molecules, the volatilizing speed from the ammine solution can be restrained.Type: GrantFiled: June 4, 2001Date of Patent: April 29, 2003Assignee: Cataler CorporationInventors: Toshiyuki Nanami, Eisaku Kondo
-
Publication number: 20020147106Abstract: An ammine solution which can be provided at low production cost, as compared with conventional ones. The ammine solution contains an ammine compound which contains at least one of platinum and palladium, and at lease one kind of amine compound. By using the amine compound of which the boiling point is raised, as compared with that of ammonia, due to the substitution of substitution radicals for some of hydrogens in ammonia molecules, the volatilizing speed from the ammine solution can be restrained.Type: ApplicationFiled: June 4, 2001Publication date: October 10, 2002Applicant: CATALER CORPORATIONInventors: Toshiyuki Nanami, Eisaku Kondo